Since the discovery and molecular cloning of BACE1 in 1999 by severalindependent groups, this enzyme has been a tempting target for pharmacologicallowering of cerebral Aβ levels with the intent of treating or preventing AD. Here, BACE1 is linked to Alzheimer disease.